Compare Hims and Hers Health Inc (HIMS) vs Victoria's Secret & Co (VSXY) Price & Performance

HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.

The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.

Victoria's Secret (VSXY) trades at $99.97, up 1.45% today and near its 52-week high. The stock shows strong technical momentum with bullish moving averages and positive earnings surprises in three consecutive quarters. Revenue remains stable at $6.23B for 2025, while net income improved to $165M. Analyst consensus is bullish with 55.6% buy ratings and a $110 high price target, supported by recent international expansion success in China and Europe.

VSXY presents growth potential through international expansion and data-driven marketing, but faces valuation concerns with a P/E of 37.5 and competitive retail pressures. The stock's current price exceeds the consensus target, suggesting near-term consolidation risk despite positive technical momentum and improving fundamentals.